Celcuity (CELC) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Celcuity (CELC) over the past year, gaining 197.1% versus a gain of 33.4%. Over five years, CELC leads with a +260.8% price change compared with +54.4% for TNGX. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | TNGX |
|---|---|---|
| Share price | $65.78 | $21.83 |
| Market cap | $3.22B | $3.68B |
| 1-day change | -7.68% | -0.32% |
| YTD return | -34.16% | +144.47% |
| 1-year return | +33.43% | +197.12% |
| 5-year return | +260.82% | +54.38% |
| EPS (TTM) | $-4.17 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $34.39 |
| 52-week low | $45.03 | $6.69 |
| Distance from 52-week high | -56.44% | -36.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +106.96% |
| Average volume | 1.19M | 2.62M |
| Shares outstanding | 48.93M | 168.61M |
| Employees | 155 | 137 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed CELC by 163.7 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Healthcare · Biotechnology · 155 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Healthcare · Biotechnology · 137 employees
CELC vs TNGX FAQ
Which is bigger, Celcuity or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or TNGX?
TNGX returned +197.12% over the past 12 months, compared with +33.43% for CELC (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.